A CDH6-targeting antibody–drug conjugate (DAR-8) administered IV every 21 days; binds Cadherin-6 on tumor cells, is internalized, and releases a cytotoxic payload to kill CDH6-expressing cancer cells.
HS-20124 is a CDH6-targeting monoclonal antibody–drug conjugate that binds Cadherin-6 on tumor cells, is internalized, and releases a cytotoxic payload intracellularly, leading to targeted killing of CDH6-expressing cancer cells.
YES
DIRECT
The ADC binds Cadherin-6 on target cells, is internalized, and releases a cytotoxic payload inside the cell, directly killing Cadherin-6-expressing cells.
Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks signaling, promotes receptor downregulation, and mediates immune killing via ADCC/CDC.
Bispecific IgG1 monoclonal antibody that binds EGFR and MET (wild-type and select mutants), blocks receptor phosphorylation and downstream signaling, promotes receptor internalization/degradation, and induces Fc-mediated ADCC/CDC to inhibit tumor cell growth.
YES
DIRECT
Amivantamab binds EGFR on target cells and engages immune effectors via its IgG1 Fc to induce ADCC and complement-mediated lysis (CDC); receptor blockade/internalization may contribute to cell death.
Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks signaling, promotes receptor downregulation, and mediates immune killing via ADCC/CDC.
Bispecific IgG1 monoclonal antibody that binds EGFR and MET (wild-type and select mutants), blocks receptor phosphorylation and downstream signaling, promotes receptor internalization/degradation, and induces Fc-mediated ADCC/CDC to inhibit tumor cell growth.
YES
DIRECT
Amivantamab binds MET on target cells and engages Fc receptors to trigger ADCC and complement-dependent cytotoxicity (CDC), with additional receptor downregulation/signaling blockade.
Off-the-shelf allogeneic CAR T-cell therapy engineered to express a CAR targeting CLL-1 (CLEC12A) to activate T-cell cytotoxicity against AML blasts and leukemic stem cells.
Off-the-shelf allogeneic T cells engineered with a chimeric antigen receptor targeting CLL-1 (CLEC12A) recognize AML blasts and leukemic stem cells; antigen binding activates the CAR signaling domain to drive T-cell activation and cytotoxic killing of target cells via perforin/granzyme release and cytokines.
YES
DIRECT
CAR T cells recognize CLL-1 on target cells; CAR signaling activates T-cell cytotoxicity, killing targets via perforin/granzyme-mediated apoptosis (and associated immune effector mechanisms).
Off-the-shelf allogeneic CAR T-cell therapy engineered to express a CAR targeting CD33 to induce antigen-specific T-cell activation and lysis of AML cells.
Allogeneic off-the-shelf T cells are engineered to express a chimeric antigen receptor targeting CD33; upon binding CD33 on AML cells, the CAR activates T-cell signaling (CD3ζ with costimulatory domains) to induce cytokine release and perforin/granzyme-mediated lysis of the malignant cells.
YES
DIRECT
CD33-specific CAR T cells recognize CD33 and, upon CAR activation, directly kill target cells via perforin/granzyme-mediated cytolysis and apoptosis.